A pyrazolothiazole compound represented by the formula [I]: wherein, R 1 is hydrogen, alkyl or alkoxy; Z is -OR 3 or -NR 4 R 5 ; in which R 3 is alkyl, alkyl substituted with cycloalkyl, cycloalkyl, aryl or heteroaryl; R 4 is hydrogen or alkyl; R 5 is alkyl, cycloalkyl or saturated heterocyclic group, said alkyl and cycloalkyl in R 5 is optionally substituted with one or two groups selected from the group consisting of the following to : hydroxy, alkoxy, and difluoroalkoxy, cycloalkyl, cycloalkyl substituted with (difluoroalkoxy)alkyl, and cycloalkyl substituted with alkoxyalkyl, saturated heterocyclic group optionally substituted with (difluoroalkoxy)alkyl, aryl, aryl substituted with halogen, and aryl substituted with alkoxy, and nitrile, and said saturated heterocyclic group in R 5 is optionally substituted with one or two groups selected from the group consisting of the following to : alkyl, alkylcarbonyl, and alkoxycarbonyl; R 2 is hydroxy or -NHR 8 , in which R 8 is heteroaryl, heteroaryl substituted with halogen, heteroaryl substituted with alkyl, -COL 1 , -COOL 2 or -SO 2 L 3 , said L 1 is a group selected from the group consisting of the following to : alkyl, monohaloalkyl, dihaloalkyl, trihaloalkyl, and alkyl substituted with alkoxy, cycloalkyl, aryl, heteroaryl, and dialkylamino, and cycloalkylamino, said L 2 is a group selected from the group consisting of the following to : alkyl, monohaloalkyl, dihaloalkyl, trihaloalkyl, and alkyl substituted with alkoxy, cycloalkyl, and dialkylaminoalkyl, and said L 3 is alkyl or cycloalkyl, or a pharmaceutically acceptable salt thereof, or a solvate thereof. R 1 is hydrogen, alkyl or alkoxy; Z is -OR 3 or -NR 4 R 5 ; in which R 3 is alkyl, alkyl substituted with cycloalkyl, cycloalkyl, aryl or heteroaryl; R 4 is hydrogen or alkyl; R 5 is alkyl, cycloalkyl or saturated heterocyclic group, said alkyl and cycloalkyl in R 5 is optionally substituted with one or two groups selected from the group consisting of the following to : hydroxy, alkoxy, and difluoroalkoxy, cycloalkyl, cycloalkyl substituted with (difluoroalkoxy)alkyl, and cycloalkyl substituted with alkoxyalkyl, saturated heterocyclic group optionally substituted with (difluoroalkoxy)alkyl, aryl, aryl substituted with halogen, and aryl substituted with alkoxy, and nitrile, and hydroxy, alkoxy, and difluoroalkoxy, cycloalkyl, cycloalkyl substituted with (difluoroalkoxy)alkyl, and cycloalkyl substituted with alkoxyalkyl, saturated heterocyclic group optionally substituted with (difluoroalkoxy)alkyl, aryl, aryl substituted with halogen, and aryl substituted with alkoxy, and nitrile, and said saturated heterocyclic group in R 5 is optionally substituted with one or two groups selected from the group consisting of the following to : alkyl, alkylcarbonyl, and alkoxycarbonyl; alkyl, alkylcarbonyl, and alkoxycarbonyl; R 2 is hydroxy or -NHR 8 , in which R 8 is heteroaryl, heteroaryl substituted with halogen, heteroaryl substituted with alkyl, -COL 1 , -COOL 2 or -SO 2 L 3 , said L 1 is a group selected from the group consisting of the following to : alkyl, monohaloalkyl, dihaloalkyl, trihaloalkyl, and alkyl substituted with alkoxy, cycloalkyl, aryl, heteroaryl, and dialkylamino, and cycloalkylamino, alkyl, monohaloalkyl, dihaloalkyl, trihaloalkyl, and alkyl substituted with alkoxy, cycloalkyl, aryl, heteroaryl, and dialkylamino, and cycloalkylamino, said L 2 is a group selected from the group consisting of the following to : alkyl, monohaloalkyl, dihaloalkyl, trihaloalkyl, and alkyl substituted with alkoxy, cycloalkyl, and dialkylaminoalkyl, and alkyl, monohaloalkyl, dihaloalkyl, trihaloalkyl, and alkyl substituted with alkoxy, cycloalkyl, and dialkylaminoalkyl, and said L 3 is alkyl or cycloalkyl, or a pharmaceutically acceptable salt thereof, or a solvate thereof. <EOS>